A new study showed that compared to non-carriers, ATM, CHEK2, and PALB2 carriers showed similar mortality from breast cancer, pancreatic cancer, and colorectal cancer. Other findings among BRCA1/2 carriers and Lynch Syndrome patients showed: Why is this important?These results may be reassuring for ATM, CHEK2, and PALB2 carriers, and provide additional useful information when discussing …
Permanent link to this article: https://inheritedcancer.net/post060625/
Below is a featured video from the June 2025 case conference, during which Joanne Kotsopoulos, PhD from the Women’s College Hospital discusses hormonal risks in women with hereditary breast and ovarian cancer syndrome.
Permanent link to this article: https://inheritedcancer.net/video61225/
A new study suggests that BRIP1 might be the THIRD most common gene for inherited ovarian cancer. BRCA1/2 mutations were found in almost 15%, while the frequency of mutations in other homologous recombination repair (HRR) genes among unselected ovarian cancer patients was: Why is this important?Testing in patients with ovarian cancer through inherited cancer multi-gene …
Permanent link to this article: https://inheritedcancer.net/post52325/
A new meta-analysis study looking at prior studies of PARP inhibitors in patients with metastatic castration-resistant prostate cancer and an inherited gene mutation showed: Learn more at: https://pubmed.ncbi.nlm.nih.gov/39848867/ Reference: Naqvi, et al. Eur Urol. 2025:S0302-2838(24)02760-X. PMID: 39848867.
Permanent link to this article: https://inheritedcancer.net/post52125/
Below you may watch a featured video from the October 2022 Genetics Case Conference in which ICARE Principal Investigator, Tuya Pal, MD, discusses recent updates to the National Comprehensive Cancer Network (NCCN) guidelines.
Permanent link to this article: https://inheritedcancer.net/video100622/
